{
    "nct_id": "NCT01276353",
    "title": "A Randomized, Double Blind, Parallel-Group Comparison Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia",
    "status": "COMPLETED",
    "last_update_time": "2014-08-05",
    "description_brief": "The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with severe Alzheimer's disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "E2020 SR 23 mg",
                    "description": "E2020 SR 23 mg 1 tablet + E2020 10 mg placebo tablet once daily in the morning for 2 weeks in the double-blind phase. E2020 SR 23 mg once daily in the morning for 52 weeks in the extension phase."
                },
                {
                    "id": "FG001",
                    "title": "E2020 10 mg",
                    "description": "E2020 10 mg 1 tablet + E2020 SR 23 mg placebo tablet once daily in the morning for 2 weeks in the double-blind phase. E2020 SR 23 mg once daily in the morning for 52 weeks in the extension phase."
                }
            ],
            "periods": [
                {
                    "title": "Double-blind",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "22"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "23"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "19"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "23"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "3"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Extension",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "19"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "23"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "12"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "14"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "7"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "9"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "5"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal of study drug 4 days in a row",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "3"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "1"
                                }
                            ]
                        },
                        {
                            "type": "Physician Decision",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "Prohibited concomitant medications",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "1"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "E2020 SR 23 mg",
                    "description": "E2020 SR 23 mg 1 tablet + E2020 10 mg placebo tablet once daily in the morning for 2 weeks in the double-blind phase. E2020 SR 23 mg once daily in the morning for 52 weeks in the extension phase."
                },
                {
                    "id": "BG001",
                    "title": "E2020 10 mg",
                    "description": "E2020 10 mg 1 tablet + E2020 SR 23 mg placebo tablet once daily in the morning for 2 weeks in the double-blind phase. E2020 SR 23 mg once daily in the morning for 52 weeks in the extension phase."
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "22"
                        },
                        {
                            "groupId": "BG001",
                            "value": "23"
                        },
                        {
                            "groupId": "BG002",
                            "value": "45"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "Years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "79.3",
                                            "spread": "9.8"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "73.6",
                                            "spread": "10.8"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "76.4",
                                            "spread": "10.6"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "16"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "16"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "32"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "7"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "13"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Hachinski Score",
                    "description": "The Hachinski Ischaemic Score (HIS) is an attempt to differentiate Alzheimer's type dementia and multi-infarct dementia. It uses a system of 13 features of with a score of 1 or 2, adding the scores together for a final score. A cut-off score less than or equal to 4 for Dementia of Alzheimer's Type (DAT) and greater than or equal to 7 for Vascular Dememntia (VaD) has a sensitivity of 89% and a specificity of 89%.",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "Scores on a Scale",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1.1",
                                            "spread": "1.3"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0.7",
                                            "spread": "1.1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0.9",
                                            "spread": "1.2"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "SECONDARY",
                    "title": "Cmax of E2020 on Visits 2 and 3 According to Cytochrome P450 2D6 (CYP2D6) Phenotype Status",
                    "description": "All subjects were identified as Extensive Metabolizer \\[EM\\] or Intermediate Metabolizer \\[IM\\] predicted from their CYP2D6 phenotypes. Ultra-rapid Metabolizer (UM) and Poor Metabolizer (PM) were not identified in any subject. Since the analysis population i",
                    "populationDescription": "Pharmacokinetic Analysis Set",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "ng/mL",
                    "timeFrame": "Visit 2 [Day1] and Visit 3 [Day 15]",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "E2020 SR 23 mg",
                            "description": "E2020 SR 23 mg 1 tablet + E2020 10 mg placebo tablet once daily in the morning for 2 weeks in the double-blind phase. E2020 SR 23 mg once daily in the morning for 52 weeks in the extension phase."
                        },
                        {
                            "id": "OG001",
                            "title": "E2020 10 mg (EM)",
                            "description": "E2020 10 mg 1 tablet + E2020 SR 23 mg placebo tablet once daily in the morning for 2 weeks in the double-blind phase. E2020 SR 23 mg once daily in the morning for 52 weeks in the extension phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "22"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "23"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Visit 2 EM [IR: n=16, SR: n=17]",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "117.999",
                                            "spread": "28.898"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "98.117",
                                            "spread": "32.323"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Visit 2 IM [IR: n=5, SR: n=4]",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "161.363",
                                            "spread": "18.761"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "104.294",
                                            "spread": "23.962"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Visit 3 EM [IR: n=16, SR: n=15]",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "116.771",
                                            "spread": "31.663"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "63.896",
                                            "spread": "20.662"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Visit 2 IM [IR: n=5, SR: n=3]",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "182.953",
                                            "spread": "48.422"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "79.802",
                                            "spread": "24.984"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Maximum Observed Plasma Concentration (Cmax) of E2020 on Visits 2 and 3",
                    "populationDescription": "Pharmacokinetic Analysis Set: the group of subjects who had received at least one quantifiable E2020 concentration in plasma",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "ng/mL",
                    "timeFrame": "Visit 2 [Day1] and Visit 3 [Day 15]",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "E2020 SR 23 mg",
                            "description": "E2020 SR 23 mg 1 tablet + E2020 10 mg placebo tablet once daily in the morning for 2 weeks in the double-blind phase. E2020 SR 23 mg once in the morning daily for 52 weeks in the extension phase."
                        },
                        {
                            "id": "OG001",
                            "title": "E2020 10 mg",
                            "description": "E2020 10 mg 1 tablet + E2020 SR 23 mg placebo tablet once daily in the morning for 2 weeks in the double-blind phase. E2020 SR 23 mg once daily in the morning for 52 weeks in the extension phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "22"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "23"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Visit 2",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "126.503",
                                            "spread": "31.27"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "97.006",
                                            "spread": "32.934"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Visit 3",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "127.335",
                                            "spread": "40.654"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "66.081",
                                            "spread": "24"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "timeFrame": "Up to 54 weeks",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "E2020 SR 23 mg (Double-blind)",
                    "description": "E2020 SR 23 mg 1 tablet + E2020 10 mg placebo tablet once daily in the morning for 2 weeks in the double-blind phase.",
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 22,
                    "otherNumAffected": 13,
                    "otherNumAtRisk": 22
                },
                {
                    "id": "EG001",
                    "title": "E2020 10 mg (Double-blind)",
                    "description": "E2020 10 mg 1 tablet + E2020 SR 23 mg placebo tablet once daily in the morning for 2 weeks in the double-blind phase.",
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 23,
                    "otherNumAffected": 2,
                    "otherNumAtRisk": 23
                },
                {
                    "id": "EG002",
                    "title": "E2020 SR 23 mg (Extension)",
                    "description": "E2020 SR 23 mg once daily in the morning for 52 weeks in the extension phase.",
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 19,
                    "otherNumAffected": 9,
                    "otherNumAtRisk": 19
                },
                {
                    "id": "EG003",
                    "title": "E2020 10 mg (Extension)",
                    "description": "E2020 SR 23 mg once daily in the morning for 52 weeks in the extension phase.",
                    "seriousNumAffected": 1,
                    "seriousNumAtRisk": 23,
                    "otherNumAffected": 16,
                    "otherNumAtRisk": 23
                }
            ],
            "seriousEvents": [
                {
                    "term": "Ataxia",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 23
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Diarrhoea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 2,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Nausea",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 7,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Vomiting",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 4,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 7,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Electrocardiogram QT prolonged",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Weight decreased",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 3,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Decreased appetite",
                    "organSystem": "Metabolism and nutrition disorders",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 6,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 3,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 4,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Somnolence",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 4,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Eye Discharge",
                    "organSystem": "Eye disorders",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Epulis",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Gastrointestinal haemorrhage",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Oedema",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Oedema peripheral",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Blood pressure decreased",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Blood pressure increased",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Blood uric acid increased",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Dyskinesia",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Anaemia",
                    "organSystem": "Blood and lymphatic system disorders",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 23
                        }
                    ]
                },
                {
                    "term": "Constipation",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA V. 15.0",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 22
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 23
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 2,
                            "numAtRisk": 23
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true
            },
            "pointOfContact": {
                "title": "Naoki Kubota",
                "organization": "Clinical Development. JAC PCU. Eisai Co., Ltd.",
                "phone": "+81-3-3817-5245"
            }
        }
    },
    "target_category": "cognitive enhancer",
    "drug": [
        "donepezil (E2020, Aricept) \u2014 23 mg sustained release (SR) vs 10 mg immediate release (IR)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial compares two formulations/doses of donepezil (23 mg SR vs 10 mg IR) in patients with severe Alzheimer\u2019s disease. Donepezil is a reversible acetylcholinesterase inhibitor used to provide symptomatic cognitive benefit in AD rather than to target core AD pathology (amyloid or tau). \ue200cite\ue202turn1search1\ue202turn0search4\ue201",
        "Act: Extracted details \u2014 drug: donepezil (sponsor code E2020 / marketed as Aricept), interventions: 23 mg sustained\u2011release formulation versus the marketed 10 mg immediate\u2011release formulation; no placebo arm is specified in the provided description. E2020 is an internal product code for donepezil used by Eisai. \ue200cite\ue202turn1search6\ue202turn1search1\ue201",
        "Reflect: Classification justification \u2014 by the provided category definitions, donepezil is a small\u2011molecule cholinesterase inhibitor that improves cognition (symptomatic cognitive enhancer) and does not primarily act as a disease\u2011modifying agent against Alzheimer pathology; therefore the correct category is 'cognitive enhancer'. Relevant clinical evidence and regulatory descriptions note the 23 mg dose was developed/ studied to provide greater symptomatic cognitive benefit versus 10 mg in moderate\u2011to\u2011severe AD. \ue200cite\ue202turn0search4\ue202turn0search0\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial compares two formulations/doses of donepezil (E2020 / Aricept) \u2014 a centrally acting, reversible acetylcholinesterase inhibitor that increases synaptic acetylcholine to provide symptomatic cognitive benefit in Alzheimer's disease. This mechanism modulates cholinergic neurotransmission (a neurotransmitter system), not core proteinopathies like amyloid or tau. \ue200cite\ue202turn0search0\ue202turn0search11\ue201",
        "Act: Extracted details \u2014 drug: donepezil (E2020 / Aricept); intervention: 23 mg sustained\u2011release (SR) vs 10 mg immediate\u2011release (IR); target/mechanism: reversible inhibition of acetylcholinesterase to enhance cholinergic neurotransmission and improve cognition (symptomatic cognitive enhancer). The 23 mg dose/formulation has been studied/used for greater symptomatic effect in moderate\u2013severe AD. \ue200cite\ue202turn0search4\ue202turn0search6\ue201",
        "Reflect: Classification justification \u2014 CADRO groups symptomatic agents that act on neurotransmitter systems under Neurotransmitter Receptors (modulation of cholinergic signaling falls here). Donepezil acts on acetylcholinesterase to boost acetylcholine (a neurotransmitter), so D) Neurotransmitter Receptors is the most specific CADRO category. This is not a disease\u2011modifying anti\u2011amyloid/tau, anti\u2011inflammatory, or multi\u2011target trial. \ue200cite\ue202turn0search1\ue202turn0search8\ue201",
        "Web search results (key sources used):",
        "- Donepezil is a centrally acting, reversible acetylcholinesterase inhibitor (mechanism description). \ue200cite\ue202turn0search0\ue201",
        "- Donepezil (E2020 / Aricept) described as a specific/reversible AChE inhibitor used for symptomatic treatment in AD. \ue200cite\ue202turn0search1\ue202turn0search11\ue201",
        "- Product/label information and dosing (10 mg and 23 mg formulations; 23 mg studied for moderate\u2011to\u2011severe AD). \ue200cite\ue202turn0search4\ue202turn0search8\ue201"
    ]
}